Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission
A recently published study of 190 RA patients, who were in sustained remission (DAS28-CRP≤2.6) and no radiographic progression the previous year showed that Doppler Ultrasound can predict successful discontinuation of biological DMARDs. Doppler sum score was an independent predictor for successful discontinuation of biological disease-modifying anti-rheumatic drugs (bDMARDs) at 2-year follow-up – the odds for achieving successful discontinuation decreased by 56% per one-unit increase in Doppler sum score. The authors note that Ultrasound could not predict successful tapering.
The paper published in Rheumatology (Oxford), is a successful collaboration between a number of academic institutions and radiology experts. It is critical for patient care and successful assessment of treatment impact to find correlation between imaging and clinical outcomes as well as to tap into the imaging biomarker predictive power.
Title: Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission
Journal: Rheumatology (Oxford), 2021 Mar 20
Authors: Lene Terslev, Cecilie Heegaard Brahe, Merete Lund Hetland, Stylianos Georgiadis, Karen Ellegaard, Lars Juul, Tuan Huynh, Uffe Møller Døhn, Viktoria Fana, Torsten Møller, Simon Krabbe, Lykke Midtbøll Ørnbjerg, Daniel Glinatsi, Henrik Røgind, Anette Hansen, Jesper Nørregaard, Søren Jacobsen, Dorte Vendelbo Jensen, Natalia Manilo, Karsten Asmussen, Mikael Boesen, Zoreh Rastiemadabadi, Lone Morsel-Carlsen, Jakob Møllenbach Møller, Niels Steen Krogh, Mikkel Østergaard
Access Online: https://doi.org/10.1093/rheumatology/keab276
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin
Join us at BIO International Convention in Boston 5th-8th June 2023
Drug development ideas in osteoarthritis, psoriatic arthritis and scleroderma.
The Invitation-only network for founders &CEOs of the most successful scaleups.